169760-16-1

Usage

Uses

Used in Pharmaceutical Industry:
2-Acetamidophenylboronic acid is used as a key reactant for the preparation of a wide range of biologically active compounds, which are essential in the development of new drugs and therapeutic agents. Its applications include:
1. Highly substituted acenes: These are synthesized via rhodium-catalyzed oxidative coupling with alkynes, which are important for the development of advanced materials with potential applications in organic electronics and photovoltaics.
2. Anticancer pyrimidines: 2-Acetamidophenylboronic acid is used in the synthesis of pyrimidines with multiple-kinase inhibitory effects, which are crucial in the development of targeted cancer therapies.
3. 3,4-ring fused 7-azaindoles and deazapurines: These compounds are potent JAK2 inhibitors, which play a significant role in the treatment of various cancers and inflammatory diseases.
4. Polycyclic azaindoles: These are synthesized as JAK2 inhibitors, which are essential in the development of targeted therapies for cancer and autoimmune disorders.
5. ROS1 receptor tyrosine kinase inhibitors: 2-Acetamidophenylboronic acid is used in the synthesis of inhibitors targeting the ROS1 receptor tyrosine kinase, which is overexpressed in certain types of cancers and is a potential therapeutic target.
6. 2-aminopyrazolopyridines: These compounds are synthesized as Polo-like kinase 1 (PLK1) inhibitors, which are important in the development of anticancer drugs targeting cell division and proliferation.

InChI:InChI=1/C8H10BNO3/c1-6(11)10-8-5-3-2-4-7(8)9(12)13/h2-5,12-13H,1H3,(H,10,11)

Upstream product

• 5570-18-3 2-aminophenylboronic acid 
• 75-36-5 acetyl chloride 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1056162-18-5 N-[2-(9-oxo-9H-xanthen-3-yl)-phenyl]-acetamide 
• 1029806-21-0 1-(2'-acetylaminobiphenyl-4-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 1092063-06-3 C₂₉H₂₆ClN₅O 
• 1036243-86-3 N-(2-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetamide 
• 1234327-24-2 N-(2-(5-(2-aminopyrimidin-4-yl)pyridin-2-yl)phenyl)acetamide 
• 1232411-84-5 N-(2-(5-amino-6-(5-phenyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)phenyl)ethanamide 
• 1192885-80-5 [5-(3-methoxy-5-methylphenyl)-4-(2-(2-acetamidophenyl)pyridin-4-yl)-pyrazol-1-yl]acetonitrile 
• 1192885-62-3 [3-(3-methoxy-5-methylphenyl)-4-(2-(2-acetamidophenyl)pyridin-4-yl)-pyrazol-1-yl]acetonitrile 
• 1269823-69-9 2-(7H-pyrrolo[2,3-c]pyridazin-4-yl)aniline 
• 1239-56-1 1-(2,3-diphenyl-1H-indol-1-yl)ethan-1-one 
• 1352874-25-9 N-[4'-(2-amino-benzoimidazol-1-yl)-biphenyl-2-yl]-acetamide 
• 1352872-32-2 N-{4'-[3-(2-chloro-benzyl)-2-imino-2,3-dihydro-benzoimidazol-1-yl]-biphenyl-4-yl}-acetamide 
• 68267-69-6 N-acetyl-2-allylaniline 
• 2143475-98-1 N-(2-(9H-carbazol-1-yl)phenyl)acetamide 

Relevant academic research and scientific papers

Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3

Fused heterotricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.

Novel compounds and their use as positive AMPA receptor modulators

The invention provides novel compounds represented by the general formula 5 compound represented by the formula: wherein the bond represented by the broken line may be a single, a double bond or absent; and if the bond is absent, then the nitrogen is substituted with a hydrogen and R2; X represents SO2 or C═O or CH2; Y represents —CH(R4)—, —N(R4)— or —N(R4)—CH2—, O; and the meaning of R2, R3, R4, R5, R6, R7, and R8 are as defined in the application The compounds are useful as positive modulators of the AMPA-receptor.